Prenatal genetic screening now extends beyond risk assessment to intervening before birth, when treatment can still prevent irreversible harm. Early intervention is critical for many inherited diseases. A devastating inherited disease that destroys nerve cells in the brain and spinal cord is one example. In its most severe form, children may not survive early childhood.

A new program attempts to use prenatal genetic information about the disease to deliver in-utero gene therapy. This is a real-world test of a simple principle for hereditary disease presented in earlier stories and in my book Destiny’s Child No Longer: Rewriting Genetic Fate . Test the family, test the fetus and, when possible, correct the mutation before birth rather than accept avoidable harm.

Family-based testing provides a practical starting point. This is called carrier screening. It checks the parents to see if they carry any hidden gene changes that do not affect them but could cause problems if passed to their child. Carrier screening in parents, followed by targeted prenatal diagnosis, establishes a direct path from genetic risk identification to intervention.

If both parents carry a risk for the same disease, the infant can then be screened during pregnancy to determine whether they have inherited the condition. This careful testing helps doctors spot risks early, sometimes even before a child is born. One of the main tools is called cell-free fetal DNA testing. Imagine being able to learn about a baby’s genetic health from just a small sample of the mother’s blood, long before birth. Currently, these tests focus on chromosomal abnormalities, but with additional diagnostic steps, they could identify other serious conditions and inform treatment planning.

The approach is straightforward: test parents , test the fetus and intervene before birth when a treatable disorder is identified. This can change a family's story from facing a life-altering diagnosis to having hope for a healthier future. Real strides are being made in this direction, as seen in a new study targeting the most devastating types of disease that begin harming a baby’s brain and body before birth. These diseases often have no warning signs until the damage is already underway, making early detection and intervention absolutely critical.

Faulty Gene Derails Early Development

The most recent trial focuses on GM1 Gangliosidosis , a severe inherited disorder caused by harmful mutations in the gene that encodes a helper enzyme that breaks down certain natural substances inside our cells. When the encoding gene does not work properly, the enzyme is missing. As a result, waste materials build up in the body. This buildup occurs substantially in the brain, like garbage piling up when the trash collectors stop coming. Over time, this damages cells and leads to serious health problems.

There are different forms of this disease based on when symptoms first appear. The type that strikes infants is the most devastating. At first, babies may seem to develop normally. Soon their progress slows, and the muscles needed for movement grow weak. Over time, children lose abilities they had just learned, such as sitting, crawling or reaching for toys. Some develop seizures, and many have trouble seeing as their vision fades. These children usually do not survive past early childhood.

Gene therapy can help older infants and children by delivering a healthy copy of the missing gene, but if treatment is delayed until symptoms have begun, it cannot undo damage already done to the brain and body. This is why it is critical to find and treat these illnesses as early as possible—ideally before birth, when there is still a chance to protect the brain and other organs from lasting harm.

A new trial builds directly on the results of a recent study published in the New England Journal of Medicine . The previous study illustrates the ability to diagnose serious genetic diseases in fetuses and deliver gene therapy before birth, with encouraging safety and benefit. Now, a trial is taking the next step of testing this approach in the womb for the very first time. The study focuses on families who already have a child with the disease, making it easier to diagnose the condition early in pregnancy.

When a fetus is identified as having the high-risk gene mutation, a harmless virus carrying a healthy copy of the encoding gene is injected directly into the umbilical vein. This allows the treatment to circulate through the baby's body. After birth, the children will be carefully monitored for safety, development and early signs that the therapy is working. Improvements in movement, fewer seizures and better brain growth will be tracked.

The biggest challenge in fetal therapy is ensuring it’s safe and beneficial. Measuring effects inside the womb is difficult. New ways to monitor fetuses are being developed, but questions remain about the best dose, delivery method and long-term safety. Careful evaluation will be key as the study moves forward.

This trial is about more than one disease. If the therapy proves safe and effective, it could pave the way for treating a wide range of devastating genetic disorders before birth. This would offer hope to families who previously faced only heartbreaking outcomes. Gene therapy, once a futuristic dream, could become a new standard for preventing some of the most severe childhood diseases—if we act soon enough. The journey from the earlier study’s promising results to this new trial highlights how each step forward brings us closer to real cures for families who need them most.